A new mutation in the Parkinson's‐related FBXO7 gene impairs mitochondrial and proteasomal function

Elisa Navarro,Noemí Esteras
DOI: https://doi.org/10.1111/febs.17155
2024-05-08
FEBS Journal
Abstract:Mutations in FBXO7, which encodes a substrate‐recognition subunit of the Skp1‐Cullin‐F‐box protein E3 ubiquitin ligase complex, are associated with hereditary Parkinson's disease (PD). In this issue of The FEBS Journal, Al Rawi et al. characterize a previously undescribed missense mutation in the dimerization domain of FBXO7. They show that this mutation destabilizes Fbxo7 and prevents its interaction with the proteasomal regulator PI31, impairing proteasomal and mitochondria functionality and emphasizing the role of both pathways in the pathogenesis of PD. Comment on: https://doi.org/10.1111/febs.17114. Around 10% of Parkinson's disease (PD) cases are associated with mutations in various genes, including FBXO7, which encodes the substrate‐recognition component for the Skp1‐Cullin‐F‐box (SCF) class of ubiquitin E3 ligases that target proteins for proteasomal degradation. In their recent study, Al Rawi et al. characterized a new mutation in FBXO7, L250P, in a pediatric patient. Their findings reveal that the L250P mutation abolishes Fbxo7 interaction with the proteasome regulator, proteasome inhibitor 31kD (PI31), affecting proteasomal activity and the ubiquitination of some of the ligase's targets. Furthermore, the authors show that this previously undescribed mutation impairs mitochondrial function and mitophagy, emphasizing the importance of mitochondrial and proteasomal dysfunction in PD pathogenesis.
biochemistry & molecular biology
What problem does this paper attempt to address?